Stryker officially released the first surgical software application (FDA-cleared earlier in July of this year) for use on Apple Vision Pro in an operating room.

A week later, orthopedic surgeon Dr. Chad Mather III at Duke Health performed the first hip arthroscopy using the system. He wore the headset during a procedure for femoroacetabular impingement and labral repair, with a live arthroscopy camera feed, CT imaging, HipCheck measurements, and a full surgical plan arranged in virtual panels around his operative field. All while maintaining unobstructed sight of the patient, the instruments, and the room behind those panels.

I have been waiting for something like this for a long time. And I want to explain why the authorization itself matters more than the product.

It Was Never About Whether It Was Possible

I performed the first surgery using Google Glass in 2013, so the capability to overlay clinical information into a surgeon's visual field has existed in some technical form for many years. Companies like Medivis have been building augmented reality surgical tools for the better part of a decade. The question was never whether spatial computing could work in an operating room. In controlled demonstrations and research settings, it clearly could.

The question was whether a major medical device company would build something properly, submit it through a rigorous regulatory pathway, and create the institutional infrastructure for this technology to actually reach clinical practice at scale.

Stryker just answered that question. SportSuite Vision went through FDA De Novo authorization — a pathway used for novel low- to moderate-risk devices that don't have a direct regulatory predicate. The July 17 decision didn't just clear one product. It created an entirely new Class II device category for augmented-reality surgical display systems. That category is now the regulatory blueprint for every application that follows. What Stryker built is a product. What the FDA authorized is a framework.

The Regulatory Detail Worth Understanding

De Novo matters for a specific reason in this context. In the FDA's medical device framework, a De Novo authorization creates a predicate. A legally established device type against which future devices can be compared for clearance. Before July 17, there was no predicate for an AR surgical display system used during live procedures. Now there is.

That means the companies building the next generation of spatial computing applications for the OR have a regulatory pathway to work from. The friction of being first is gone. The questions the FDA will ask have been answered once, which means they will be answered faster the second time.

This is also why the specific classification of SportSuite Vision matters. Stryker's application was authorized as a medical display device (not as diagnostic software). The CT imaging it displays is designated for information rather than diagnosis. That distinction may seem technical, but it determines the scope of responsibility, the liability framework, and the level of clinical scrutiny the device carries. Every spatial computing company building for clinical environments needs to understand exactly where that line sits and how their application relates to it.

What This Looks Like in Practice

SportSuite Vision's initial authorization is narrow by design. It is cleared for hip arthroscopy procedures involving femoroacetabular impingement and labral repair. The FDA requires a conventional monitor to remain available as a backup. Other OR staff use standard displays while the surgeon wears the headset.

That narrowness is appropriate. De Novo authorization is a first step, not a final destination. What the Duke Health case demonstrated is the practical value of the concept in a real surgical environment. Dr. Mather described being able to move clinical information to fit his workflow and access it from within the sterile field without breaking scrub. This is actually a very meaningful ergonomic and safety improvement over turning to look at a wall-mounted screen mid-procedure.

Every surgeon who has had to redirect their attention during a delicate operative moment to find information on a monitor across the room understands why that matters.

The Apple Vision Pro Question

People keep telling me that Apple Vision Pro is dying. That the headset layoffs are a signal of retreat. That spatial computing in healthcare has stalled. I look at the release calendar and see something different.

Every few days, a new clinical application ships for the Vision Pro. Healthcare has become one of the most active development categories for the platform precisely because the device's capabilities (the resolution, the passthrough camera quality, the spatial audio, the precision of the eye and hand tracking) are genuinely well suited to clinical environments in ways that earlier AR hardware was not.

Stryker's authorization will accelerate this. It demonstrates to every medical device company still sitting on spatial computing prototypes that the regulatory pathway is navigable and that FDA will engage with this category seriously. The waitlist Stryker has opened for surgical teams interested in SportSuite Vision will give them the real-world feedback to iterate. Other companies watching will begin their own submissions soon.

The rollout will be measured and procedurally specific, as it should be. But the direction is no longer uncertain.

Where This Is Going

The most compelling version of this technology is not a single headset for the primary surgeon with a backup monitor on the wall. That is the first generation.

The next generation is the full spatial OR (every screen, every analog display, every paper checklist replaced by a personalized spatial view for each member of the surgical team). The surgeon seeing what the surgeon needs. The scrub nurse seeing instrument layout and counts. The circulator seeing room status and patient vitals. The surgical assistant seeing the procedure plan from their angle of the field.

Each role, each perspective, each information set. All personalized, spatially arranged, AI-optimized in real time using the data that already exists about this patient, this procedure, this team.

A company I advise, eXeX, founded by my friend and colleague Robert Masson, is building exactly this. They are among the most serious teams working on the full-OR spatial computing model, and what they are developing represents what this category looks like when you stop thinking about it as a display upgrade and start thinking about it as an operating room redesign.

The Stryker authorization is one application, in one procedure type, on one platform. But the category it just created is large enough to contain everything that comes next.

The OR of 2030 is being built right now, clearance by clearance. This week was a meaningful one.

——————————————————————————————————————

Dr. Rafael Grossmann is a trauma surgeon, digital health innovator, and global keynote speaker focused on the intersection of technology and human-centered medicine. He speaks on AI in healthcare, physician burnout, and the future of patient care.